In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
- 8 August 2014
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 29 (3), 705-714
- https://doi.org/10.1038/leu.2014.238
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapyLeukemia, 2013
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasoneBritish Journal of Haematology, 2013
- Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expressionBritish Journal of Haematology, 2012
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tidesBlood, 2012
- Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacyBlood, 2012
- Multiple MyelomaNew England Journal of Medicine, 2011
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia, 2009
- Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genomeCytogenetic and Genome Research, 2006
- The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug ResistanceCancer Research, 2006